SEC Filing Summary: GRI Bio, Inc. (Form 8-K)
Business Context and Reporting Period
GRI Bio, Inc., a Delaware corporation listed on the Nasdaq Capital Market under the symbol "GRI," filed this Current Report on Form 8-K on February 4, 2026. The filing serves to reiterate the Company's financial results for the fiscal year 2025 and summarize key recent highlights via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release (Exhibit 99.1) referenced in the report but are not explicitly stated in the body of this Form 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document functions as a conduit to the press release containing the fiscal year 2025 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, outlook, or risk factors are enumerated in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 4, 2026) for specific fiscal year 2025 financial figures.
- Verify the Company's status as an Emerging Growth Company (indicated as yes in the filing).
- Confirm that the financial data in the press release is not automatically incorporated by reference into future filings.
- Check for any subsequent filings that may provide detailed breakdowns of the "key recent highlights" mentioned.